# Akebia Therapeutics (AKBA) — Earnings

AKBA · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/akba/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.03 |
| EPS estimate | −$0.04 |
| EPS surprise | +28.57% |
| Revenue surprise | +0.56% |
| Revenue | $49.1M |
| Revenue estimate | $48.9M |
| Reported | Aug 5, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1517022/000151702226000051/akba-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/d322df23-dabb-5081-181a-bbf2d165e112.html) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 5, 2026 | −$0.04 | −$0.03 | 28.57% | $48.9M | $49.1M |
| Q1 2026 | May 7, 2026 | −$0.03 | −$0.03 | -7.14% | $51.7M | $53.5M |
| Q4 2025 | Feb 26, 2026 | −$0.04 | −$0.05 | -38.89% | $46.1M | $57.6M |
| Q3 2025 | Nov 10, 2025 | −$0.01 | $0.00 | 100.00% | $58.2M | $58.8M |
| Q2 2025 | Aug 7, 2025 | −$0.02 | $0.00 | 100.00% | $47.2M | $62.5M |
| Q1 2025 | May 8, 2025 | −$0.04 | $0.03 | 178.95% | $44.5M | $57.3M |
| Q4 2024 | Mar 13, 2025 | −$0.08 | −$0.10 | -23.92% | $37.3M | $46.5M |
| Q3 2024 | Nov 7, 2024 | −$0.06 | −$0.10 | -57.98% | $44.5M | $37.4M |
| Q2 2024 | Aug 8, 2024 | −$0.07 | −$0.04 | 44.67% | $49.8M | $43.6M |
| Q1 2024 | May 9, 2024 | −$0.07 | −$0.09 | -25.00% | $46.1M | $32.6M |
| Q4 2023 | Mar 14, 2024 | −$0.04 | $0.00 | 100.00% | $55.4M | $56.2M |
| Q3 2023 | Nov 8, 2023 | −$0.09 | −$0.08 | 5.88% | $48.2M | $42.0M |
| Q2 2023 | Aug 25, 2023 | −$0.03 | −$0.06 | -140.00% | $59.1M | $56.4M |
| Q1 2023 | May 8, 2023 | −$0.15 | −$0.14 | 3.45% | $46.7M | $40.1M |
| Q4 2022 | Mar 9, 2023 | −$0.18 | −$0.04 | 78.18% | $47.4M | $55.2M |
| Q3 2022 | Nov 3, 2022 | −$0.17 | −$0.28 | -64.71% | $48.9M | $49.0M |
| Q2 2022 | Aug 4, 2022 | −$0.32 | $0.15 | 146.40% | $53.0M | $126.8M |
| Q1 2022 | May 9, 2022 | −$0.29 | −$0.35 | -21.99% | $44.3M | $61.7M |
| Q4 2021 | Mar 1, 2022 | −$0.31 | −$0.40 | -31.15% | $51.8M | $59.6M |
| Q3 2021 | Nov 4, 2021 | −$0.32 | −$0.34 | -6.25% | $49.6M | $48.8M |

## Frequently Asked Questions

### When did Akebia Therapeutics (AKBA) last report earnings?

Akebia Therapeutics last reported on Aug 5, 2026, covering fiscal Q2 2026.

### Did AKBA beat earnings estimates?

Yes. Akebia Therapeutics reported EPS of −$0.03 for Q2 2026 against a −$0.04 estimate — a 28.57% beat.

### How much revenue did AKBA report last quarter?

Akebia Therapeutics reported $49.1M in revenue for Q2 2026, against a consensus estimate of $48.9M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).